Focus and think clearly

Everyone in these 45 studies was short on sleep, at six hours or under or awake for a full day, so nothing here says what caffeine does for someone who slept well. The benefit kept rising with dose without the review ever finding the point where it stops rising, so the top of that range is unmapped.

The 11 trials used a spread of doses and designs rather than one fixed ratio, so this is a pattern across mixtures rather than a test of any single blend. The authors call theanine's contribution comparatively modest rather than absent, which leaves room for a larger pool to move it. And every trial pooled here tested combinations, so none of it measures theanine by itself.

One trial of 48 people, and it was designed to study caffeine, with theanine as the modifier rather than the subject. For anyone taking theanine by itself for calm focus, the same trial is a null result: alertness, jitteriness and mood did not move.

This measures anticholinergic burden as a whole, not diphenhydramine and not antihistamines. Only 8 of the 25 studies found could be pooled at all. The scales used to score that burden agree poorly with one another, so what is being measured is not the same thing from study to study.

This was whole matcha, theanine and catechins and caffeine together, so no result here belongs to theanine specifically. The two results that moved were secondary outcomes, which carry less weight than the ones the trial was built to test. And everyone in it already had cognitive decline, which is not a healthy adult drinking green tea.

Participants were picked for being unusually healthy for their age, with no major health event in five years and good mobility, so a frailer group might respond differently. Testing six outcomes at once, the authors demanded a p value below 0.01, a strict bar that would hide a modest real effect. Three years is short for both fractures and cognition.

All of them were older outpatients with diabetes, many on metformin, so this is not a general older-adult sample. Forty-four percent already had questionable dementia at the start, which may put some of the decline beyond reach. Borderline-low is not outright deficiency.

Forty people took the dose, and each took it once, so this shows what one sharp rise does rather than what months of raised cortisol do. The loss was confined to recalling facts and handling space, which leaves much of what memory does unaffected.

The group was small and elderly, and the published summary never says how many people were in it. In humans this is a correlation; the evidence that cortisol itself damages the structure comes from the rat work the same paper cites. Ageing or illness could equally shrink that structure and raise cortisol at once, which would draw this same pattern with no link between them.

The subgroup finding that carries this claim is reported without a formal test of interaction, so it is suggestive rather than demonstrated. Six of the eighteen studies had no control group, and their effect sizes run two to three times larger, which is what an uncontrolled design predicts. Only 204 of the 1,408 participants were children or adolescents.

Sixty-eight people were recruited and 41 finished, against the researchers' own target of 60. The company that makes the capsule funded the trial and pays five of the authors. Three of the four people who quit over side effects were taking lion's mane.

The mycelium here grew in stirred liquid, not on grain, so this settles which tissue makes erinacines and not how much of a grain-grown powder is mushroom. Only four erinacines were measured, and the assay's detection floor is not stated.

This paper set out to test safety, not to measure composition, so the oat description is an incidental disclosure rather than a finding. No independent laboratory has ever assayed a commercial lion's mane product and published the result.

This panel carries no new data of its own and was answering a narrow question about one disease, so its refusal to recommend lion's mane there is not a verdict on memory claims in general. What does travel is its flat report that the memory finding stands unrepeated.

People who eat mushrooms differ from people who do not in diet quality, income and how much they move, and any of those could be doing the work. The observational half covers all mushroom species, so none of that signal belongs to lion's mane in particular.

These are not four points on one scale. Fruiting-body powder and mycelium are different tissue carrying different compounds, so a gram of one is not a gram of the other, and the range above is what has been tried rather than what has been optimised.

The same review sorts those eighteen ingredients by evidence and puts lion's mane in its best-supported group, but that sorting is one team's judgement with no stated inclusion rules and no bias assessment. Its own closing paragraph says the category lacks a solid scientific foundation.

Nobody swallowed anything: these were extracts applied to platelets in a tube, at concentrations matching no serving or capsule. The same paper's introduction cites an earlier report that a lion's mane extract did interfere with one platelet receptor, so even the tube evidence is split.

2000mg per kilogram was the highest dose tried, not a limit anyone established, and a rat no-harm level is not a human intake limit. No human safety measure was taken. The company selling the powder ran and wrote it. An expert panel review records one anaphylactic reaction to fresh lion's mane.

The 28-day stress result that gets quoted came in at p=0.051, just outside the usual cutoff for calling a result real. The authors call this a pilot too small to conclude from. What was in the capsule was described only as a proprietary mushroom complex.

Everyone studied already had normal B12, so this says nothing about people who are actually short of it. Several of the pooled trials gave B12 inside a B complex alongside folate, so the B12-only signal rests on fewer studies. The fatigue gap is an absence of trials, not a pooled null.

The trial was built as a caffeine comparison, so the pairing was never its main question. Accuracy was one of several measures taken in that task. The advantage was over placebo, and caffeine alone was credited on a different measure, so nothing here sets the pair against caffeine by itself.

What this trial cannot show is whether the pair beats caffeine alone: its edge was over placebo, on one brief task. The edge is unconfirmed rather than contradicted.

A single two-hour task. Theanine's effect showed up in behaviour but not in the brain-wave marker much of this field leans on, so the two kinds of evidence do not line up here. And it disagrees with a similarly dosed trial that did find an advantage for the combination.

What is open is whether pairing theanine with caffeine helps attention generally or only on the brief task that found it. Counting errors over two hours in 27 people, the pair did no better than either alone.

The participants skewed middle-aged and older, and most were women. A long list of outcomes was tested at once, which on its own makes some of the positive ones likely to be chance.

The corrected reanalysis is the original authors' own reply rather than an independent check. The surviving older-adult effect rests on a small number of trials within those 8. And in younger adults the effect was flat before the correction and flat after it.

A memory benefit reported across healthy adults vanished once scores from the same people stopped being counted as different people. The effect in 66-to-76-year-olds survived that correction, and it is the finding worth weighing.

The English null is wide: a real 20 to 30% increase sits inside its range. The Taiwanese comparison group is small, 36,081 non-users against 677,971 users, and people with hay fever who take nothing are unlikely to resemble those who do. Neither design separates the drug from the reason it was taken.

Whether antihistamines raise dementia risk is unsettled. English prescription records show no significant link, Taiwanese dispensing records a rise with dose, and English records miss most shop-bought use, so neither can correct the other.

The conditions these drugs treat, insomnia and low mood among them, are early signs of dementia themselves, so the drug may be marking the illness rather than causing it. Dropping the last twelve months of use blunts that without removing it. One health system in Seattle, shop-bought use only partly captured.

A pattern shared by drugs that do and do not reach the brain points somewhere other than the drug. More medicine dispensed means more medical contact and more chances for a diagnosis to be recorded, and heavier users are sicker to begin with. The authors call for trials to confirm any association.

This is a single snapshot in time, so it cannot say which came first. The finding sits inside a subgroup defined by poor B12 status, well under the 1858 people surveyed, which is where chance findings live, and the authors describe some of their own results as unexpected and internally inconsistent. In the people whose B12 was normal, more of the natural circulating folate went with better scores, not worse.

Placebo improved on its own baseline too, which is what within-arm comparisons look like when practice and expectation are doing the work. Nothing here runs longer than two hours. The sponsor sells the tea extract used as the comparator.

Nobody has measured what lion's mane does in a human bloodstream, in any form, so none of this is confirmed in a person. Erinacines are made by the mycelium, so a fruiting-body capsule is not carrying the compound this study followed.

The search covered PubMed alone, so anything indexed only elsewhere or published in another language is missing, and nothing after June 2024 is included. The review's own design labels are wrong in places: it files one placebo-controlled trial as a cohort study.

Lion's mane's cognitive benefits come from small, short, often maker-funded trials, while independent trials in healthy adults found nothing against placebo. It is less a dispute than too little evidence to have one.

No lion's mane product was tested here; this is a different fungus and none of these numbers transfers. The analysts work for a supplier selling fruiting-body extracts in competition with grain-grown mycelium ones, which is a direct commercial interest in this result.

No person received either compound. The doses that worked on cultured cells and in mice have no translation into a capsule, and blocking that receptor only partly stopped the effect, so even the pathway is unsettled.

The cells were a human tumour line, not ordinary brain tissue, and the mouse arm fed animals 5% lion's mane powder for a week, a far larger share of the diet than anyone eats. Nerve growth factor messenger levels are a molecular reading, not a memory test.

Three research groups each point to a different active compound in lion's mane, and the one printed on most labels failed when tested alone. None has been tested in a person, so what does the work is still open.

This is reishi, a different fungus, and no lion's mane product was in the sample. Nineteen batches is small, the sampling method is undescribed, and 'matched the label' means matched by these analysts' own chemical criteria, which another method would score differently. The data predate 2017.

The lead author works in a mushroom producer's own laboratory, and an independent expert panel reviewing the trial in 2024 reported that nobody had repeated it. The outcome was a brief dementia screening questionnaire, not a full memory assessment.

This is electrical activity recorded in one small single-lab study, not behaviour and not how focused anyone felt or performed. A distinct signature is not the same thing as better concentration.

The trial reported which way each measure moved, not by how much. Nine people took each treatment, and three published papers all describe the same 27. The caffeine was a slow-release tablet, not coffee.